Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 1 · 33.3%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

CLOZAPINE + AMISULPIRIDE vs CLOZAPINE + QUETIAPINE (Genc 2007)

Weight gain · people with treatment‐resistant schizophrenia

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
GRADE not reported

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics

Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants · patients with schizophrenia

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).

1 finding from 1 review

Sulpiride augmentation for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.3 [0.09, 0.99]
1 study · 64 participants
Low

CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)

Weight gain · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + RISPERIDONE changes adverse effects: weight gain compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
RR 0.4 [0.08, 1.9]
1 study · 60 participants
Very low